April 30, 2026 · Form 4 insider transaction
Behrndt-Eriksen Mads Nikolaj bought 49,016 shares of Hemab Therapeutics Holdings, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 4 days after the transaction.
This option was granted on April 30, 2026. The shares underlying the option will vest over four years in equal monthly installments from May 1, 2026 through May 1, 2030.